This week on Surfing the NASH Tsunami, we are offering a co-host ‘roundtable’ catch-up between Jörn Schattenberg, Louise Campbell and Roger Green. This is a fun, casual conversation that looks into first quarter highlights and a preview of what’s to come in quarter two of 2023.
Roger begins this session by describing some of his anticipations around drug development in the second quarter, specifically pointing to emerging news on OCA and resmetirom. He also notes the possibility of new Phase 3 press releases on the horizon. Louise comments that with expected drug approvals, there needs to be more emphasis around allied health education, training and pathways. This leads Roger to share his belief that an approval in the US will lead to rather aggressive allied health education.
If you enjoy the episode, have questions or interest around its contents and Fatty Liver disease, we kindly ask that you submit reviews wherever you download our discussions. Alternatively, you can write to us directly at questions@SurfingNASH.com.